The Globe and Mail reports in its Wednesday, Sept. 25, edition that analysts at Canaccord Genuity believe that uranium equities have "decoupled from the underlying commodity price with little regard to the bullish commentary emanating following the [World Nuclear Symposium] earlier this month." The Globe's David Leeder writes that Canaccord analyst Katie Lachapelle continues to rate Uranium Royalty "speculative buy." She gave her share target a 25-cent trim to $6.50. Analysts on average target the shares at $7.10. Canaccord analysts say in a note: "The supply shortfall has not magically evaporated, the global build-out of traditional nuclear has not slowed, but rather accelerated, and the pace of SMR development has, if anything, increased. With our underlying thesis still very much intact (we retain our $90 (U.S.)/lb long-term price forecast) we see a compelling opportunity. ... Uranium equities have defied an improving term price, experiencing an 8-per-cent decline year-to-date vs. an 18-per-cent increase in the reported term price. The recent pullback in uranium equities, amidst a steady climb in the term price, has been highly uncharacteristic and has created the largest divergence between the Global X ETF and the long-term price."